Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

323
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
323
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

385
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
385
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

4.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.9K
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

40
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
40
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

569
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
569
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

54
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
54

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Satisfaction and Decisional Regret After Mesh Versus Non-Mesh Apical Pelvic Organ Prolapse Surgery.

Neurourology and urodynamics·2026
Same author

Reply to Editorial Comment on "Prescribing Patterns for Beta-3 Agonists and Anticholinergic Medications Used in Treatment of Overactive Bladder".

Urology·2025
Same author

Prescribing Patterns for Beta-3 Agonists and Anticholinergic Medications Used in Treatment of Overactive Bladder.

Urology·2025
Same author

Impact of United States Food and Drug Administration Position Statements on Complication Rates Within 30 Days After Stress Urinary Incontinence Sling Surgery.

Urology practice·2025
Same author

Evaluation of Financial Toxicity in Women Seeking Care for Urinary Incontinence.

Urogynecology (Philadelphia, Pa.)·2025
Same author

A Randomized Controlled Trial of Percutaneous Tibial Nerve Stimulation in the Treatment of Female Sexual Dysfunction.

Neurourology and urodynamics·2025

Related Experiment Video

Updated: Sep 23, 2025

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.4K

Combination and Novel Pharmacologic Agents for OAB.

Whitney Clearwater1, Farzaan Kassam2, Arshia Aalami Harandi3

  • 1Department of Obstetrics & Gynecology and Women's Health, Division of Female Pelvic Medicine and Reconstructive Surgery, Montefiore Medical Center / Albert Einstein College of Medicine, 1250 Waters Place, Tower Two, 9th floor, Bronx, NY, 10461, USA.

Current Urology Reports
|May 14, 2022
PubMed
Summary

Combination therapies and novel pharmacologic treatments show improved efficacy for overactive bladder (OAB) compared to single-drug approaches. These advanced strategies offer better outcomes for managing OAB symptoms.

Keywords:
Combination therapyNovel therapyOveractive bladder

More Related Videos

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.1K
Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction
06:01

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction

Published on: October 6, 2022

1.6K

Related Experiment Videos

Last Updated: Sep 23, 2025

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.4K
Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.1K
Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction
06:01

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction

Published on: October 6, 2022

1.6K

Area of Science:

  • Urology
  • Pharmacology
  • Nephrology

Background:

  • Overactive bladder (OAB) is a complex condition involving neural, muscular, and urothelial dysfunction.
  • Current treatments often have high discontinuation rates and limited efficacy.

Purpose of the Study:

  • To review recent literature on combination and novel pharmacologic therapies for overactive bladder (OAB).

Main Methods:

  • Literature review of recent studies on OAB treatments.
  • Analysis of combination therapies and novel pharmacologic agents.

Main Results:

  • Combination therapies (e.g., anticholinergics with β-3 agonists or neuromodulation) are more effective than monotherapy.
  • Novel agents like selective anticholinergics, new β-3 agonists, and gabapentin show promise.

Conclusions:

  • Diversifying therapeutic targets through combination therapy enhances OAB treatment efficacy.
  • Novel treatments targeting additional pathways represent a promising future direction for OAB management.